Navigation Links
TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
Date:10/1/2008

ther indications, the potential for NGX426 to be analgesic, the anticipated timing of results for the NGX426 study in a model of capsaicin-induced pain, the potential for NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, the anticipated timing of results from the study of NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, and the ability to partner any of the company's product candidates or programs. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine and/or other indications for which they are developed, that NGX267 will successfully
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, 2015 /PRNewswire/ ... health care services and one of the largest ... that its parent company and sole stockholder, Capella ... Medical Properties Trust, Inc. ("MPT") (NYSE: MPW ... cash.  The transaction is expected to be finalized ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... Biophotonics industry.The report provides a basic overview of the industry including definitions, classifications, ... international markets including development trends, competitive landscape analysis, and key regions development status. ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... facility identification solutions, today announced a new video: 3 Ways to GHS ... Hazard Communication Standard and the Globally Harmonized System (GHS) by effectively labeling chemical ...
(Date:7/27/2015)... July 27, 2015 Research presented at the ... expand on the studies that led to a fingerprick ... for this disease to receive approval from the World ... breaking Ebola,s grip on West Africa ... enabling healthcare workers to isolate and treat these patients ...
Breaking Biology Technology:Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Brady Releases “3 Roads to GHS Labels” Video 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... BEIJING, May 21 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: ... Rock Resources Inc. has been assigned a new symbol ... become effective on May 21, 2009,according to NASDAQ. , ... in conducting Hollow Fiber Mambrane,Materials, application and manufacturing business ...
... 21 Sinobiopharma Inc. ("Sinobiopharma ", or "the ... announce that it has applied for two Chinese ... pre-surgical skeletal muscle relaxant. The Company has applied ... a Chinese patent for Atracurium,s freeze-drying compounds (Application ...
... Moving Toward Genotype-Guided Psychotropic TherapySAN FRANCISCO, May 21 ... and Director of Genetics Research at Hartford Hospital ... at the Mayo Clinic will co-chair a symposium, ... Depressive Disorders ," at the annual meeting of ...
Cached Biology Technology:RainEarth Inc. Changes Trading Symbol from GRKR to RNER 2Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate 2Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association 2
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... 2008) This months issue of Cold Spring ... understand developmental processes in plants and flies. Both methods ... Web site for Cold Spring Harbor Protocols ( ... RNAi to investigate gene function in fruit flies. Short ...
... BIRMINGHAM, Ala. Scientists at the University of Alabama ... crystallography to uncover new details about the infectious potency ... in viral infections can subvert the bodys immune system. ... will speed the discovery of new drugs to combat ...
... of Miamis Rosenstiel School of Marine and Atmospheric ... J. McGillicuddy, Jr., Ph.D., as recipient of the ... the department of Applied Ocean Physics and Engineering ... Woods Hole, Mass., is a pioneer in the ...
Cached Biology News:RNA-based methods for developmental studies are featured in Cold Spring Harbor Protocols 2Poxvirus potency uncovered in new atomic map 2Oceanographer Dennis J. McGillicuddy, Jr. receives 34th annual Rosenstiel Award 2
...
BD IMagnet 1 each...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Biology Products: